Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
Peter Zanvit(AstraZeneca (Finland)), Emily E. Bosco(Early Intervention Foundation)
Cited by 49
Related Papers
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
|Journal of Clinical Investigation|2006|192